Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ACAD |
---|---|---|
09:32 ET | 12674 | 15.01 |
09:34 ET | 1500 | 15.07 |
09:36 ET | 1856 | 15.04 |
09:38 ET | 617 | 15.04 |
09:39 ET | 400 | 15.035 |
09:41 ET | 5465 | 14.99 |
09:43 ET | 53950 | 15.04 |
09:45 ET | 6746 | 15.03 |
09:48 ET | 3191 | 15.005 |
09:50 ET | 3055 | 14.985 |
09:52 ET | 1683 | 14.98 |
09:54 ET | 3971 | 14.97 |
09:56 ET | 10100 | 14.97 |
09:57 ET | 2150 | 14.96 |
09:59 ET | 507 | 14.9692 |
10:01 ET | 4438 | 14.9275 |
10:03 ET | 1762 | 14.93 |
10:06 ET | 1742 | 14.93 |
10:08 ET | 550 | 14.94 |
10:10 ET | 5189 | 14.91 |
10:12 ET | 5976 | 14.93 |
10:14 ET | 1997 | 14.905 |
10:15 ET | 3257 | 14.97 |
10:17 ET | 1006 | 14.97 |
10:19 ET | 2501 | 14.97 |
10:21 ET | 2900 | 14.96 |
10:24 ET | 2609 | 14.97 |
10:26 ET | 1000 | 14.99 |
10:28 ET | 827 | 15 |
10:30 ET | 2532 | 14.98 |
10:32 ET | 2100 | 14.965 |
10:33 ET | 800 | 14.96 |
10:35 ET | 2550 | 14.94 |
10:37 ET | 2200 | 14.9486 |
10:39 ET | 9118 | 14.925 |
10:42 ET | 15670 | 14.935 |
10:44 ET | 1630 | 14.935 |
10:46 ET | 4180 | 14.93 |
10:48 ET | 23249 | 14.985 |
10:50 ET | 400 | 15 |
10:51 ET | 8959 | 14.98 |
10:53 ET | 2770 | 14.96 |
10:55 ET | 5472 | 14.95 |
10:57 ET | 1000 | 14.95 |
11:00 ET | 2942 | 14.96 |
11:02 ET | 500 | 14.9575 |
11:04 ET | 7704 | 14.94 |
11:06 ET | 600 | 14.95 |
11:08 ET | 600 | 14.945 |
11:09 ET | 3440 | 14.925 |
11:11 ET | 3599 | 14.925 |
11:13 ET | 4340 | 14.93 |
11:15 ET | 6364 | 14.91 |
11:18 ET | 3002 | 14.885 |
11:20 ET | 9287 | 14.9 |
11:22 ET | 714 | 14.89 |
11:24 ET | 2200 | 14.87 |
11:26 ET | 5548 | 14.88 |
11:27 ET | 1596 | 14.885 |
11:29 ET | 1200 | 14.88 |
11:31 ET | 5296 | 14.905 |
11:33 ET | 3164 | 14.905 |
11:36 ET | 2400 | 14.87 |
11:38 ET | 12056 | 14.88 |
11:40 ET | 3290 | 14.9 |
11:42 ET | 1661 | 14.89 |
11:44 ET | 1732 | 14.8901 |
11:45 ET | 1659 | 14.891 |
11:47 ET | 850 | 14.9 |
11:49 ET | 1996 | 14.9 |
11:51 ET | 4089 | 14.885 |
11:54 ET | 1000 | 14.885 |
11:56 ET | 800 | 14.885 |
11:58 ET | 2619 | 14.8875 |
12:00 ET | 100 | 14.89 |
12:02 ET | 2004 | 14.895 |
12:03 ET | 900 | 14.9 |
12:05 ET | 700 | 14.9 |
12:07 ET | 1378 | 14.9 |
12:09 ET | 3201 | 14.89 |
12:12 ET | 533 | 14.9 |
12:14 ET | 1100 | 14.89 |
12:16 ET | 2615 | 14.885 |
12:18 ET | 1000 | 14.88 |
12:20 ET | 2000 | 14.88 |
12:21 ET | 1704 | 14.88 |
12:23 ET | 4078 | 14.885 |
12:25 ET | 3795 | 14.89 |
12:27 ET | 2299 | 14.875 |
12:30 ET | 1200 | 14.865 |
12:32 ET | 4288 | 14.85 |
12:34 ET | 5515 | 14.83 |
12:36 ET | 4488 | 14.835 |
12:38 ET | 3109 | 14.835 |
12:39 ET | 1803 | 14.84 |
12:41 ET | 1336 | 14.84 |
12:43 ET | 1440 | 14.85 |
12:45 ET | 1200 | 14.84 |
12:48 ET | 1719 | 14.835 |
12:50 ET | 1500 | 14.84 |
12:52 ET | 1100 | 14.835 |
12:54 ET | 4319 | 14.835 |
12:56 ET | 713 | 14.83 |
12:57 ET | 3847 | 14.845 |
12:59 ET | 719 | 14.845 |
01:01 ET | 2059 | 14.865 |
01:03 ET | 3119 | 14.885 |
01:06 ET | 1000 | 14.89 |
01:08 ET | 2400 | 14.885 |
01:10 ET | 1614 | 14.9 |
01:12 ET | 4387 | 14.88 |
01:14 ET | 1583 | 14.875 |
01:15 ET | 4126 | 14.87 |
01:17 ET | 2250 | 14.855 |
01:19 ET | 1100 | 14.855 |
01:21 ET | 3271 | 14.855 |
01:24 ET | 2684 | 14.85 |
01:26 ET | 2000 | 14.84 |
01:28 ET | 3651 | 14.845 |
01:30 ET | 1751 | 14.84 |
01:32 ET | 1150 | 14.83 |
01:33 ET | 4559 | 14.85 |
01:35 ET | 2181 | 14.885 |
01:37 ET | 1600 | 14.885 |
01:39 ET | 3641 | 14.88 |
01:42 ET | 1600 | 14.87 |
01:44 ET | 2150 | 14.85 |
01:46 ET | 1093 | 14.86 |
01:48 ET | 2300 | 14.87 |
01:50 ET | 3554 | 14.8664 |
01:51 ET | 974 | 14.86 |
01:53 ET | 5651 | 14.87 |
01:55 ET | 2934 | 14.86 |
01:57 ET | 3164 | 14.835 |
02:00 ET | 1700 | 14.82 |
02:02 ET | 5792 | 14.825 |
02:04 ET | 1090 | 14.82 |
02:06 ET | 3760 | 14.88 |
02:08 ET | 2106 | 14.87 |
02:09 ET | 2212 | 14.87 |
02:11 ET | 800 | 14.87 |
02:13 ET | 1700 | 14.87 |
02:15 ET | 1980 | 14.875 |
02:18 ET | 1400 | 14.8703 |
02:20 ET | 4115 | 14.9 |
02:22 ET | 1127 | 14.9 |
02:24 ET | 3300 | 14.89 |
02:26 ET | 2539 | 14.89 |
02:27 ET | 2800 | 14.89 |
02:29 ET | 995 | 14.89 |
02:31 ET | 1000 | 14.89 |
02:33 ET | 8132 | 14.91 |
02:36 ET | 4074 | 14.885 |
02:38 ET | 5329 | 14.88 |
02:40 ET | 2138 | 14.885 |
02:42 ET | 3726 | 14.875 |
02:44 ET | 2044 | 14.88 |
02:45 ET | 4200 | 14.89 |
02:47 ET | 1157 | 14.885 |
02:49 ET | 628 | 14.885 |
02:51 ET | 5544 | 14.88 |
02:54 ET | 1200 | 14.885 |
02:56 ET | 2300 | 14.9 |
02:58 ET | 2759 | 14.895 |
03:00 ET | 3923 | 14.905 |
03:02 ET | 700 | 14.9 |
03:03 ET | 3952 | 14.93 |
03:05 ET | 2500 | 14.94 |
03:07 ET | 3500 | 14.945 |
03:09 ET | 5939 | 14.94 |
03:12 ET | 2111 | 14.945 |
03:14 ET | 3834 | 14.945 |
03:16 ET | 1614 | 14.945 |
03:18 ET | 2636 | 14.945 |
03:20 ET | 3100 | 14.93 |
03:21 ET | 5462 | 14.9299 |
03:23 ET | 5303 | 14.93 |
03:25 ET | 6810 | 14.95 |
03:27 ET | 3751 | 14.94 |
03:30 ET | 3837 | 14.93 |
03:32 ET | 2306 | 14.95 |
03:34 ET | 7933 | 14.95 |
03:36 ET | 5707 | 14.95 |
03:38 ET | 1827 | 14.95 |
03:39 ET | 8342 | 14.935 |
03:41 ET | 6163 | 14.94 |
03:43 ET | 11400 | 14.935 |
03:45 ET | 9461 | 14.92 |
03:48 ET | 5090 | 14.92 |
03:50 ET | 9478 | 14.915 |
03:52 ET | 15638 | 14.905 |
03:54 ET | 20525 | 14.885 |
03:56 ET | 33616 | 14.88 |
03:57 ET | 46613 | 14.895 |
03:59 ET | 63446 | 14.91 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
ACADIA Pharmaceuticals Inc | 2.5B | -1,158.5x | --- |
Azenta Inc | 2.9B | -19.7x | --- |
PTC Therapeutics Inc | 2.7B | -4.7x | --- |
Novavax Inc | 2.0B | -4.5x | --- |
Guardant Health Inc | 3.7B | -7.7x | --- |
Genmab A/S | 17.4B | 22.0x | +22.71% |
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.5B |
---|---|
Revenue (TTM) | $813.8M |
Shares Outstanding | 165.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.37 |
EPS | $-0.01 |
Book Value | $2.62 |
P/E Ratio | -1,158.5x |
Price/Sales (TTM) | 3.0 |
Price/Cash Flow (TTM) | 275.4x |
Operating Margin | -0.56% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.